1. Home
  2. IMXI vs MLYS Comparison

IMXI vs MLYS Comparison

Compare IMXI & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo International Money Express Inc.

IMXI

International Money Express Inc.

HOLD

Current Price

$15.48

Market Cap

458.3M

Sector

Technology

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$33.13

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMXI
MLYS
Founded
1994
2019
Country
United States
United States
Employees
N/A
N/A
Industry
Retail: Computer Software & Peripheral Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
458.3M
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
IMXI
MLYS
Price
$15.48
$33.13
Analyst Decision
Buy
Strong Buy
Analyst Count
3
7
Target Price
$16.67
$47.33
AVG Volume (30 Days)
231.2K
1.5M
Earning Date
02-25-2026
02-11-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.29
N/A
Revenue
$625,123,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$0.95
N/A
P/E Ratio
$12.01
N/A
Revenue Growth
N/A
N/A
52 Week Low
$8.58
$8.24
52 Week High
$21.41
$47.65

Technical Indicators

Market Signals
Indicator
IMXI
MLYS
Relative Strength Index (RSI) 64.72 29.64
Support Level $15.32 $34.21
Resistance Level $15.43 $37.70
Average True Range (ATR) 0.06 1.56
MACD -0.01 -0.13
Stochastic Oscillator 70.45 14.42

Price Performance

Historical Comparison
IMXI
MLYS

About IMXI International Money Express Inc.

International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: